Medical devices; classification/reclassification; restricted devices; analyte specific reagents--FDA. Final rule

Area of Science:

• Regulatory Science
• Medical Device Classification
• In Vitro Diagnostics

Background:

• Analyte specific reagents (ASRs) are critical components in various diagnostic tests.
• Previous classification and regulation of ASRs, particularly pre-1976 devices, lacked consistency.
• The Food and Drug Administration (FDA) sought to harmonize the regulatory approach for ASRs.

Purpose of the Study:

• To establish a final rule for the classification and regulation of analyte specific reagents (ASRs).
• To define risk-based classifications for ASRs, ranging from low to high risk.
• To implement appropriate regulatory controls, including exemptions and restrictions, for ASRs.

Main Methods:

• Reclassification of low-risk ASRs to Class I (general controls) with exemption from premarket notification (510(k)).
• Classification of ASRs for specific blood banking tests into Class II (special controls) due to insufficient general controls.
• Classification or retention of high-risk ASRs in Class III (premarket approval).

Main Results:

• ASRs are classified into Class I (low risk), Class II (moderate risk, e.g., certain blood banking tests), and Class III (high risk).
• All ASRs are designated as restricted devices, with specific limitations on sale, distribution, and use.
• The final rule applies consistently to both pre- and post-1976 ASR devices.

Conclusions:

• The FDA's final rule provides a risk-based regulatory framework for ASRs.
• This harmonization ensures appropriate oversight for ASRs, balancing public health protection with regulatory efficiency.
• The rule clarifies the regulatory status of ASRs while maintaining exemptions for reagents under the Public Health Service Act and for nonclinical settings.